WO2004028448A2 - Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs - Google Patents

Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs Download PDF

Info

Publication number
WO2004028448A2
WO2004028448A2 PCT/US2003/028701 US0328701W WO2004028448A2 WO 2004028448 A2 WO2004028448 A2 WO 2004028448A2 US 0328701 W US0328701 W US 0328701W WO 2004028448 A2 WO2004028448 A2 WO 2004028448A2
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
inflammation
glutamate
effective amount
pain
Prior art date
Application number
PCT/US2003/028701
Other languages
English (en)
Other versions
WO2004028448A9 (fr
WO2004028448A3 (fr
Inventor
Kenneth E. Miller
Original Assignee
Miller Kenneth E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/029108 external-priority patent/WO2003022261A1/fr
Priority claimed from US10/660,093 external-priority patent/US7504231B2/en
Application filed by Miller Kenneth E filed Critical Miller Kenneth E
Priority to AU2003294221A priority Critical patent/AU2003294221A1/en
Publication of WO2004028448A2 publication Critical patent/WO2004028448A2/fr
Publication of WO2004028448A3 publication Critical patent/WO2004028448A3/fr
Publication of WO2004028448A9 publication Critical patent/WO2004028448A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Abstract

L'invention concerne une composition à propriétés d'atténuation durable de la douleur susceptible d'être administrée pour l'atténuation de douleur chronique. Cette composition comprend une quantité efficace d'au moins un inhibiteur de synthèse des neurotransmetteurs. L'invention concerne également un procédé d'atténuation de douleur chronique pendant une durée étendue, avec administration du composé sur un site d'inflammation, de manière à réduire au moins l'une des réponses de douleur thermique et mécanique sur le site d'inflammation, pendant une durée d'au moins deux jours, sans composante de douleur aiguë. La composition peut aussi renfermer une quantité efficace d'au moins un composé à effets analgésiques, de manière à atténuer la douleur aiguë.
PCT/US2003/028701 2002-09-13 2003-09-12 Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs WO2004028448A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003294221A AU2003294221A1 (en) 2002-09-13 2003-09-12 Method of alleviating pain via inhibition of neurotransmitter synthesis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US41131102P 2002-09-13 2002-09-13
US10/245,098 2002-09-13
PCT/US2002/029108 WO2003022261A1 (fr) 2001-09-13 2002-09-13 Methode pour soulager la douleur
USPCT/US02/29108 2002-09-13
US60/411,311 2002-09-13
US10/245,098 US7288246B2 (en) 2001-09-13 2002-09-13 Method of alleviating chronic pain via peripheral glutaminase regulation
US10/660,093 US7504231B2 (en) 2001-09-13 2003-09-11 Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
US10/660,093 2003-09-11

Publications (3)

Publication Number Publication Date
WO2004028448A2 true WO2004028448A2 (fr) 2004-04-08
WO2004028448A3 WO2004028448A3 (fr) 2004-09-30
WO2004028448A9 WO2004028448A9 (fr) 2004-12-02

Family

ID=33479689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028701 WO2004028448A2 (fr) 2002-09-13 2003-09-12 Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs

Country Status (2)

Country Link
AU (1) AU2003294221A1 (fr)
WO (1) WO2004028448A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1752143A1 (fr) * 2005-08-08 2007-02-14 NewThera Nouvelle utilisation d'agents visant la synthétase de glutamine
WO2007058612A1 (fr) * 2005-11-15 2007-05-24 Entress Ab Medicament a utiliser en rapport avec la deterioration de cartilage
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
JP2018528261A (ja) * 2015-07-31 2018-09-27 ザ・ジョンズ・ホプキンス・ユニバーシティー グルタミン類似体のプロドラッグ
US10323086B2 (en) 2002-12-24 2019-06-18 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN111139270A (zh) * 2019-12-23 2020-05-12 浙江大学 一种用于生产l-草铵膦的酶组合和l-草铵膦生产方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013672A (en) * 1997-12-18 2000-01-11 Uab Research Foundation Agonists of metabotropic glutamate receptors and uses thereof
US6291523B1 (en) * 1997-08-28 2001-09-18 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291523B1 (en) * 1997-08-28 2001-09-18 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
US6013672A (en) * 1997-12-18 2000-01-11 Uab Research Foundation Agonists of metabotropic glutamate receptors and uses thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US8088384B2 (en) 2002-12-24 2012-01-03 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US10323086B2 (en) 2002-12-24 2019-06-18 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US11008386B2 (en) 2002-12-24 2021-05-18 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
EP1752143A1 (fr) * 2005-08-08 2007-02-14 NewThera Nouvelle utilisation d'agents visant la synthétase de glutamine
WO2007017768A2 (fr) * 2005-08-08 2007-02-15 Newthera Nouvelles utilisations pour medicaments ciblant la glutamine synthetase
WO2007017768A3 (fr) * 2005-08-08 2008-10-30 Newthera Nouvelles utilisations pour medicaments ciblant la glutamine synthetase
WO2007058612A1 (fr) * 2005-11-15 2007-05-24 Entress Ab Medicament a utiliser en rapport avec la deterioration de cartilage
RU2454999C2 (ru) * 2005-11-15 2012-07-10 Энтресс Аб Лекарственное средство, применяющееся при поражениях хряща
JP2018528261A (ja) * 2015-07-31 2018-09-27 ザ・ジョンズ・ホプキンス・ユニバーシティー グルタミン類似体のプロドラッグ
CN111139270A (zh) * 2019-12-23 2020-05-12 浙江大学 一种用于生产l-草铵膦的酶组合和l-草铵膦生产方法

Also Published As

Publication number Publication date
WO2004028448A9 (fr) 2004-12-02
AU2003294221A1 (en) 2004-04-19
AU2003294221A8 (en) 2004-04-19
WO2004028448A3 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
US7714007B2 (en) Method of alleviating chronic pain via peripheral glutaminase regulation
Xiao et al. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation
Goldlust et al. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA
Gil et al. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease
Ortel et al. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes
Hunter et al. Dietary sulphur amino acid adequacy influences glutathione synthesis and glutathione-dependent enzymes during the inflammatory response to endotoxin and tumour necrosis factor-α in rats
Tabernero et al. Lactate spares glucose as a metabolic fuel in neurons and astrocytes from primary culture
Li et al. Dietary supplementation with cysteine prodrugs selectively restores tissue glutathione levels and redox status in protein-malnourished mice
Massieu et al. Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates
Gozlan et al. Anoxic LTP is mediated by the redox modulatory site of the NMDA receptor
Dolci et al. Therapeutic induction of energy metabolism reduces neural tissue damage and increases microglia activation in severe spinal cord injury
Turner et al. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro
Ugarte et al. The localization of endogenous zinc and the in vitro effect of exogenous zinc on the GABA immunoreactivity and formation of reactive oxygen species in the retina
WO2004028448A2 (fr) Procede d'attenuation de la douleur par inhibition de la synthese des neurotransmetteurs
US7504231B2 (en) Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
WO2004075883A1 (fr) Utilisation de derives de curcumine ou de l'ester phenethylique d'acide cafeique dans la fabrication d'un medicament destine au traitement des troubles neurodegeneratifs
US20230067642A1 (en) Compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects
Cárdenas et al. Protective effect of N-(3-(aminomethyl) benzyl) acetamidine, an inducible nitric oxide synthase inhibitor, in brain slices exposed to oxygen–glucose deprivation
Seiler et al. Amplification by glycine of the anticonvulsant effect of THPO, a GABA uptake inhibitor
Martínez et al. Novel molecular targets for the prevention of fetal alcohol syndrome
Asanuma et al. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro
Hawkins et al. Brain metabolism in encephalopathy caused by hyperammonemia
Vasam et al. Nutritional regulation of mitochondrial function
Mehrzadi et al. The anticonvulsant activity of thiamine, vitamin D3, and melatonin combination on pentylenetetrazole-induced seizures in mice
Satyanarayana Metabolism of amino acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/30-30/30, DRAWINGS, REPLACED BY NEW PAGES 1/33-33/33; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP